$TRDA

$4.41 -$0.34 (7.16%) Close

$TRDA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 38.9M shares outstanding

Who owns TRDA?

By type of holder

Institutions 74.6% Insiders 25.4% Everyone else 0.0%

Concentration Top 10 holders own 97.2%

Baker Bros. Advisors LP 13.0% · Kush Parmar 10.6%

Institutional ownership

74.6%

+9.1 pts vs last qtr

Institutional holders

127

+8 vs last qtr

Net shares bought

+3.6M

by institutions in Q2 2026

New / sold out

25 / 17

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Merck & Co., Inc. NEW +1.7M
MPM Bioimpact LLC NEW +1.3M

Biggest sellers in Q2 2026

TCG Crossover Management, LLC −1.2M
Jones Hill Capital LP SOLD OUT −374.0K

Who is planning to sell?

Notices of proposed sale, last 12 months

$4.04M

9 notices from 4 people

Shares covered

457.4K

1.17% of the company

Arranged in advance

30%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

5AM Ventures V, L.P. Affiliated stockholder $2.85M
Kory Wentworth Officer 10b5-1 $415K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2020–FY2025

+3643.1%

+106.37% a year

Each share's claim on the business

−97.3%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $63.4M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years69% 1–3 years14% Under 1 year16%

Quarterly turnover

17.2%

of institutional shares changed hands

Top 10 managers, median time held

4.5 years

Super Investors

Investment managers reporting TRDA on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
BB Baker Bros. Advisors LP	5.1M	13.03%	Unchanged	2021	0.2%
Shares held by quarter Peak holding5.1M (Q4'25) Change over 8 quarters+206.9K Share of the company13.030% Baker Bros. Advisors LP's full portfolio →
5V 5AM Venture Management, LLC	4.1M	10.42%	Unchanged	2021	10.4%
Shares held by quarter Peak holding4.4M (Q3'24) Change over 8 quarters−352.0K Share of the company10.420% 5AM Venture Management, LLC's full portfolio →

Baker Bros. Advisors LP

5.1M

% of company

13.03%

Change vs last qtr

Unchanged

Held since

2021

5AM Venture Management, LLC

4.1M

% of company

10.42%

Change vs last qtr

Unchanged

Held since

2021

28 more super investors behind a free account

See every manager holding Entrada Therapeutics, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting TRDA on Form N-PORT; together they hold 14.8% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$7.02M	953.7K	2.45%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$5.65M	768.0K	1.97%	0.01%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$7.02M

% of company

2.45%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$5.65M

% of company

1.97%

% of the fund

0.01%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Entrada Therapeutics, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
KP Kush Parmar 5%+ holder 13D · 10.8%	4.1M	10.59%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.590% Disclosed stake13D · 10.8% View the 13D/G filing →
AJ Andrew J. Schwab 5%+ holder 13D · 10.6%	4.1M	10.42%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.420% Disclosed stake13D · 10.6% View the 13D/G filing →

Kush Parmar

5%+ holder13D · 10.8%

4.1M

% of company

10.59%

Change vs last qtr

—

Held since

—

Andrew J. Schwab

5%+ holder13D · 10.6%

4.1M

% of company

10.42%

Change vs last qtr

—

Held since

—

22 more holders behind a free account

See every insider and 5%+ holder of Entrada Therapeutics, Inc..

Comments